Zelenectide pevedotin
Peptide
Also known as BT8009
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Development in Non-Small Cell Lung Cancer stopped (2026-03) as a strategic decision by the sponsor. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06225596 NCT06225596 · Urothelial Carcinoma Registry: NCT06225596 | 2 | Cohort 1: Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, version 1.1(RECIST v1.1) by blinded central independent review (BICR) of optimal dose zelenectide pevedotin with pembrolizumab versus chemotherapy (Up to approximately 4 years); Cohort 2: PFS per RECIST v1.1 assessed by BICR of zelenectide pevedotin monotherapy in each treatment regimen (Up to approximately 4 years); Cohort 2: Objective response rate (ORR) per RECIST v1.1 assessed by BICR of zelenectide pevedotin monotherapy in each treatment regimen (Up to approximately 4 years) 2028-03 | In progress: results expected 1 Mar 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other Nectin-4 drugs
Enfortumab Vedotin, Notiretatug rezetecan, Sutantatug envedotin, IPH4502, LY4052031. Compare all 6 Nectin-4 drugs
5 other tracked programmes target this mechanism, 3 of them ahead of this one.
This drug's own stage for Urothelial Carcinoma: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zelenectide Pevedotin: this drug | Phase 2 | Peptide | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Avelumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Enfortumab Vedotin | Approved(overall) | Antibody–drug conjugate | Nectin-4 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Erdafitinib (Balversa) | Approved | Small molecule | FGFR1-4 | Weak signal | Featured results are dose-finding and non-efficacy only in this race | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT03036098: Sub-study (cisplatin-eligible), nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin: PFS HR 0.72 (95% CI 0.59 to 0.88), p=0.0018; OS median 21.7 vs 18.9 months, HR 0.78 (95% CI 0.63 to 0.96), p=0.0171. Primary study, nivolumab + ipilimumab vs chemotherapy: OS in PD-L1 >=1% 16.3 vs 14.4 months, primary not met per BMS; OS in cisplatin-ineligible 19.1 vs 13.2 months, HR 0.79 (95% CI 0.64 to 0.97), posted p=0.0032 (CT.gov posted results). | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02853305: Pembrolizumab plus chemotherapy vs chemotherapy: PFS median 8.3 vs 7.1 months (HR 0.78, 95% CI 0.65 to 0.93; p=0.0033 against a boundary of 0.0019); OS median 17.0 vs 14.3 months (HR 0.86, 95% CI 0.72 to 1.02; p=0.0407 against a boundary of 0.0142). Pembrolizumab monotherapy OS comparisons were exploratory after the hierarchy stopped (KEYNOTE-361, Lancet Oncol 2021). missed | |
| Datopotamab Deruxtecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Disitamab Vedotin | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Phase 3 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ipilimumab | Phase 3 | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Notiretatug Rezetecan | Phase 3 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Govitecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sutantatug Envedotin | Phase 3 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tremelimumab | Phase 3 | Monoclonal antibody | CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Budigalimab | Phase 2 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| GI-101A | Phase 1/2 | Protein / enzyme therapeutic | CTLA-4 / IL-2Rβγ | not yet graded | No reviewed efficacy summary in this indication | |
| AKY-1189 | Phase 1 | Radiopharmaceutical | Nectin-4 (PVRL4) | not yet graded | No reviewed efficacy summary in this indication | |
| IPH4502 | Phase 1(overall) | Antibody–drug conjugate | Nectin-4 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| LY4052031 | Phase 1 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Zelenectide pevedotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
January 2027 (1)
What to watch
2028 (3)
March 2028 (1)
What to watch
June 2028 (1)
What to watch
August 2028 (1)
What to watch
2030 (1)
May 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent